Cargando…

Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy

Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by s...

Descripción completa

Detalles Bibliográficos
Autores principales: Omori, Teppei, Sasaki, Yu, Koroku, Miki, Murasugi, Shun, Yonezawa, Maria, Nakamura, Shinichi, Tokushige, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101788/
https://www.ncbi.nlm.nih.gov/pubmed/35566620
http://dx.doi.org/10.3390/jcm11092494
_version_ 1784707173346967552
author Omori, Teppei
Sasaki, Yu
Koroku, Miki
Murasugi, Shun
Yonezawa, Maria
Nakamura, Shinichi
Tokushige, Katsutoshi
author_facet Omori, Teppei
Sasaki, Yu
Koroku, Miki
Murasugi, Shun
Yonezawa, Maria
Nakamura, Shinichi
Tokushige, Katsutoshi
author_sort Omori, Teppei
collection PubMed
description Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by small-bowel capsule endoscopy (SBCE). Methods: We examined patients with a Crohn’s Disease Activity Index (CDAI) value < 150 and a C-reactive protein (CRP) value < 0.5 mg/dL with SB or SB colonic CD. The presence of small-bowel ulcerative lesions (≥0.5 cm) was grouped by SBCE results, and we then compared the groups’ LRG value to establish a cutoff value for screening for the presence of lesions. Results: In 40 patients with CD, the LRG values differed significantly between the patients with and without SB ulcerative lesions (Ul + 14.1 (2.1–16.5) μg/mL vs. Ul − 12.3 (9.3–13.5) μg/mL; p = 0.0105). The respective cutoff LRG values for the presence of SB ulcerative lesions was 14 μg/mL (areas under the ROC curve 0.77), with sensitivity 63.6%, specificity 82.8%, positive predictive values 58.3%, negative predictive values 85.7%, and accuracy 78%. Conclusion: These results indicate that LRG may be useful in predicting the presence of SB inflammation associated in patients with CD with CRP < 0.5 mg/dL and CDAI < 150, and in selecting patients for SBCE.
format Online
Article
Text
id pubmed-9101788
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91017882022-05-14 Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy Omori, Teppei Sasaki, Yu Koroku, Miki Murasugi, Shun Yonezawa, Maria Nakamura, Shinichi Tokushige, Katsutoshi J Clin Med Article Background: Small bowel (SB) lesions in quiescent Crohn’s disease (CD) are sometimes not identified by clinical activity or existing markers. We investigated the usefulness of a novel biomarker, leucine-rich α2-glycoprotein (LRG), for screening for the presence of SB ulcerative lesions detected by small-bowel capsule endoscopy (SBCE). Methods: We examined patients with a Crohn’s Disease Activity Index (CDAI) value < 150 and a C-reactive protein (CRP) value < 0.5 mg/dL with SB or SB colonic CD. The presence of small-bowel ulcerative lesions (≥0.5 cm) was grouped by SBCE results, and we then compared the groups’ LRG value to establish a cutoff value for screening for the presence of lesions. Results: In 40 patients with CD, the LRG values differed significantly between the patients with and without SB ulcerative lesions (Ul + 14.1 (2.1–16.5) μg/mL vs. Ul − 12.3 (9.3–13.5) μg/mL; p = 0.0105). The respective cutoff LRG values for the presence of SB ulcerative lesions was 14 μg/mL (areas under the ROC curve 0.77), with sensitivity 63.6%, specificity 82.8%, positive predictive values 58.3%, negative predictive values 85.7%, and accuracy 78%. Conclusion: These results indicate that LRG may be useful in predicting the presence of SB inflammation associated in patients with CD with CRP < 0.5 mg/dL and CDAI < 150, and in selecting patients for SBCE. MDPI 2022-04-29 /pmc/articles/PMC9101788/ /pubmed/35566620 http://dx.doi.org/10.3390/jcm11092494 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Omori, Teppei
Sasaki, Yu
Koroku, Miki
Murasugi, Shun
Yonezawa, Maria
Nakamura, Shinichi
Tokushige, Katsutoshi
Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title_full Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title_fullStr Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title_full_unstemmed Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title_short Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy
title_sort serum leucine-rich alpha-2 glycoprotein in quiescent crohn’s disease as a potential surrogate marker for small-bowel ulceration detected by capsule endoscopy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101788/
https://www.ncbi.nlm.nih.gov/pubmed/35566620
http://dx.doi.org/10.3390/jcm11092494
work_keys_str_mv AT omoriteppei serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT sasakiyu serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT korokumiki serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT murasugishun serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT yonezawamaria serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT nakamurashinichi serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy
AT tokushigekatsutoshi serumleucinerichalpha2glycoproteininquiescentcrohnsdiseaseasapotentialsurrogatemarkerforsmallbowelulcerationdetectedbycapsuleendoscopy